PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...
Indeed, the next era of blockbuster cancer therapeutics could be focused on treating what ends up being the cause of death for up to 40% of cancer patients – cachexia. Historically, cachexia has ...
Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...
Frequency and incidence of oncogenic RAS mutations in patients with metastatic pancreatic ductal adenocarcinoma: Derived from the real-world evidence database Foundation Medicine Insights. Correlation ...
Two new composition of matter patents granted in the US and Europe Patents provide protection relating to lead compound S-pindolol benzoate ...
The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early ...
Actimed Therapeutics’ anti-catabolic and pro-anabolic transforming agent, S-pindolol benzoate receives US & European patents: London, UK Friday, February 7, 2025, 16:00 Hrs [IST ...
The impact of cancer cachexia on patients and the urgent need for new treatments has become increasingly apparent, and we continue to press ahead with our plans to bring our potential new therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback